# Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

> **NCT01970540** · PHASE1 · COMPLETED · sponsor: **PharmaMar** · enrollment: 122 (actual)

## Conditions studied

- Endometrial Adenocarcinomas
- Neuroendocrine Tumors
- Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy

## Interventions

- **DRUG:** lurbinectedin (PM01183)
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT01970540
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-25
- **Primary completion:** 2017-08-09
- **Final completion:** 2017-08-09
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2020-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01970540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01970540, "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01970540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*